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Arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D) is a genetic form of cardiomyopathy usually transmitted
with an autosomal dominant trait, characterized by right ventricular
myocyte loss with ﬁbrofatty replacement [1]. Clinical presentations in
patients with ARVD/C varywidely. Heart failure, ventricular arrhythmias
(VA) and sudden cardiac death (SCD) are the most severe clinical
manifestations of ARVD/C. It accounts for 11%–22% of cases of SCD in the
young athlete population. Prevention of SCD represents the primary goal
of management strategy in ARVD/C patients, and therapeutic options
include antiarrhythmic drugs, the placement of an ICD, radiofrequency
ablation and cardiac transplantation. In many cases the choice of a
correct treatment is difﬁcult due to the rarity of the disease, not allowing
a standard treatment's managing. Therapeutic strategy has to be
individualized, based on clinical presentation, risk stratiﬁcation and
physician preference [2,3]. Although several studies evaluated the
beneﬁt of the different therapeutic options, large prospective rando-
mized trials are not available. Consequently, the current therapeutic
recommendations for ARVD/C have been developed from observational
studies [4] and case series. In order to improve therapeutic efﬁcacy it is
important to classify ARVD/C patients in 4 groups (Table 1): asympto-
matic patients or healthy gene carriers, patients with hemodynamically
stable arrhythmias (such as non-sustained or sustained VT), patients
with cardiac arrest, syncope, or hemodynamically poorly-tolerated VT
and patients with refractory congestive heart failure or untreatable
ventricular arrhythmias. First group does not require prophylactic
treatment. They should however undergo cardiac follow-up andexercise
restriction especially when there is a family history of sudden death.
Indeed excessive mechanical stress, such as during competitive sports
activity and training, can aggravate theunderlyingmyocardial lesion and
accelerate disease progression [1]. In these patients moreover prophy-
lactic therapy with β-blockers could further reduce the rate of ARVD/C
progression. Pharmacologic treatments such as β-blockers and class-III
antiarrhythmic agents (sotalol and amiodarone) are commonly used to
reduce the burden of arrhythmias in patients with hemodynamically
stable arrhythmias [4]. No clinical trial has studied the efﬁcacy of
antiarrhythmic drugs in the treatment of ventricular arrhythmias in
patients with ARVD/C. Nevertheless, the evidence available has been
derived from observational studies, which have shown conﬂicting
results. The combination of beta-blockers and amiodarone has had a
beneﬁcial effect in suppression of non-sustained VT, reduction in the
frequency of sustained ventricular arrhythmias, and reduction of VT rate
preventing syncope and favoring antitachycardia pacing termination
rather than shock therapy. Catheter ablation is another option for
treatment of patients with ARVD/C who have recurrent ventricular
arrhythmias despite treatment with antiarrhythmic drugs. Ablation is
considered a complementary therapy to ICD useful to improve quality of
life by decreasing the frequency of episodes of sustained VT, symptomatic
NSVT, and ventricular ectopy. Nevertheless it may not be sufﬁcient to
prevent SCD because of the frequent relapses of VT [5]. However it is now
well-established that the outcomes of VT ablation in patients with ARVD
are improved with a combined endocardial/epicardial approach [4].
Philips B et al. recently revealed a very good short- andmid-term success
ratewith a cumulative freedom fromVTafter epicardial VTablation of 64%
and 45% at 1 and 5 years, respectively [6]. This could be explained by the
preferential epicardial inﬁltration of the disease.
Indications of ICD for primary prevention of SCD in ARVC/D
patients have not been well established [3,7]. At present ICD is
recommended in all probands whomeet TF criteria, especially if they
have a history of sudden death, sustained VT, arrhythmogenic
syncope, or a high degree of ventricular ectopy and/or nonsustained
VT on Holter monitoring. Several studies of ARVD/C probands who
received an ICD showed appropriate interventions during follow-up
in more than 50% of patients and approximately 40% were
considered life-saving based on the presence of rapid VT/VF [8,9].
We recently reported the results of a study that investigated the
therapeutic management in a group of ARVD/C patients [10].
Twenty-three patients received an ICD, and over a mean follow-up
of 6.0 ± 4.4 years, 20 patients (86%) had received appropriate ICD
therapy. An appropriate ICD shock intervention for ventricular
ﬁbrillation (VF)/ventricular ﬂutter (VFL) was seen in 12 patients (52%).
Compared with the 100% actual survival rate, VF/VFL-free survival
rate was 96%, 94% and 51% respectively at 1, 5 and 10 years of follow-up
(logrank p b 0.0001) (Fig. 1). These ﬁndings are important, as they
demonstrate that more than half of the ARVD patients treated with an
ICDexperienced appropriate ICD interventions. Finally patientswith late
complications of the disease, developing heart failure or life threatening
and untreatable VT, heart transplantation could be an optionwith good
short and long term survival. This approach is essentially the ﬁnal
therapeutic option for thesepatients [1]. ARVC/D is a progressive disease
with different genotypic and phenotypic variations that often do not
allow a standard treatment's managing. The main goal is to improve the
risk stratiﬁcation for better identiﬁcation of high risk patients, who need
the bestmanagement, from restriction of physical activity, antiarrhythmic
drugs, ICD placement, new ablation approaches with simultaneous
endocardial and epicardial ablation and, if necessary, heart transplanta-
tion. These interventions are often life saving,with thepotential to change
the natural history of the disease by offering a good quality and better life
expectancy.
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Table 1
Recommendations for clinical management in patients with ARVD.
Subgroups Recommendations
Asymptomatic patients or healthy gene carriers – Physical exercise restriction;
– Pharmacologic therapy (β-blockers and class-III antiarrhythmic agents).
Patients with hemodynamically stable arrhythmias – Pharmacologic therapy (β-blockers and class-III antiarrhythmic agents);
– Radiofrequency catheter ablation for the treatment of VA.
Patients with cardiac arrest, syncope, or hemodynamically poorly-tolerated VT – ICD implantation.
Patients with refractory congestive heart failure or untreatable ventricular arrhythmias – Heart transplantation.
Fig. 1. Kaplan–Meier analysis of survival free of VF/VFL compared with actual patient
survival. Divergence between lines reﬂects the estimated survival beneﬁt of ICD therapy.
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